
Connect Biopharma fell 80.1% from $3.15 to $0.63, behind the S&P 500's +9.7%. Its worst day was Sep 15 (−32.2%), and its low came Nov 17 at $0.58.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.27 beat the $-0.30 estimate on $0.00 revenue (est. $20,630.00).
+3.8% · S&P 500 +0.8%
EPS of $-0.34 missed the $-0.28 estimate on $169,000.00 revenue.
Story events cover the past 12 months · Times ET
+14.5% · S&P 500 −0.2%
Connect Biopharma shares rose 19.8%, while the S&P 500 rose 0.8%.
+19.8%, the year's best day · S&P 500 +0.8%
EPS of $-0.27 beat the $-0.31 estimate on $2.8M revenue (est. $4.1M).
+9.0% · S&P 500 +0.7%
Connect Biopharma shares fell 30.1%, while the S&P 500 rose 1.0%.
−30.1% · S&P 500 +1.0%
Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today
−32.2%, the year's worst day · S&P 500 −0.5%
EPS of $-0.26 beat the $-0.26 estimate on $736,000.00 revenue (est. $4.7M).
−10.0% · S&P 500 −1.0%
Where it ended: a close of $0.63 on Nov 19, 2026.
Nothing in the past 12 months.
All CNTB dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CNTB and SPY from Benzinga historical bars. Not investment advice.